Background. Recent studies showed that mineral metabolism disorders are associated with renal function loss in pre-dialysis patients, but their effects in dialysis patients are less well established. We examined associations between parameters of mineral metabolism and loss of residual renal function (RRF) in dialysis patients. Methods. We included 1468 incident haemodialysis (HD) and peritoneal dialysis (PD) patients who were not anuric at dialysis initiation from NECOSAD, a prospective multicentre cohort study. We studied the effects of plasma calcium, phosphorus, calcium-phosphorus product and intact PTH concentrations on loss of RRF. Cox regression models were applied to calculate relative risks of total loss of RRF, defined as anuria during the first 3 years of dialysis. The rate of decline of RRF over time was calculated using general linear mixed models. Results. The mean (SD) age was 59 (15), 62% were men and 59% were treated with HD. We found that both HD and PD patients with the highest phosphorus (P < 0.0001) and calcium-phosphorus product (P < 0.0001) levels had the lowest baseline residual glomerular filtration rate (rGFR) values. During follow-up, 136 HD (15%) and 67 PD patients (12%) became anuric. After adjustment for baseline rGFR, there were no significant associations between parameters of mineral metabolism and the risk of becoming anuric. There were also no differences in the rate of decline in RRF between categories of plasma concentrations. Conclusion. Disordered mineral metabolism was neither associated with the risk of becoming anuric, nor with the rate of decline in RRF in dialysis patients. Differences in decline were mainly attributable to the baseline rGFR value.
Introduction
Preserving residual renal function (RRF) is one of the primary goals for nephrologists managing patients with chronic kidney disease (CKD). Also in CKD stage V, after the initiation of dialysis therapy, preservation of RRF remains important. RRF contributes significantly to the overall health and well-being of dialysis patients [1] , and the loss of RRF predicts mortality in haemodialysis (HD) [2, 3] and peritoneal dialysis (PD) patients [4, 5] . In addition, loss of RRF contributes significantly to anaemia, inflammation and malnutrition in patients receiving dialysis treatment [4] .
Disturbances in mineral metabolism, such as secondary hyperparathyroidism and hyperphosphataemia, are common in patients receiving HD or PD therapy [6] and have been suggested as potential causes of decline of RRF. There is some evidence for a role of elevated intact parathyroid hormone (iPTH) levels in the progression of renal failure [7] . In addition, previous studies have shown that a decline in RRF leads to decreased phosphorus removal. Wang et al. reported that residual glomerular filtration rate (rGFR), despite on average being <2 ml/min/1.73 m 2 , was strongly associated with phosphorus control in PD patients [8] . Although there is evidence that a lower RRF leads to higher plasma phosphorus levels, higher plasma phosphorus levels might lead to a faster decline in RRF as well. In a rat model of CKD, associations between high plasma phosphorus concentration and both decline in renal function Mineral metabolism and RRF in dialysis patients 1581 and renal morphological changes have been shown [9] . The main external source of plasma phosphorus in humans is the protein from the diet. The effect of a protein-restricted diet on the decline in renal function has been studied extensively in CKD patients and showed a small benefit [10, 11] . These data support the hypothesis that phosphorus might be associated with the decline in RRF in humans, which was confirmed by some recent studies in pre-dialysis patients [12] [13] [14] . In addition, in one of these studies, a nonsignificant trend was observed between low plasma calcium levels and decline in RRF [13] .
There are only few previous studies that investigated whether hyperphosphataemia, or other disturbances in mineral metabolism, has a deteriorating effect on RRF in patients receiving dialysis therapy. Therefore, we aimed to determine the associations between disordered plasma calcium, phosphorus, calcium-phosphorus (Ca × P) product and iPTH concentrations, and the decline in RRF in a large prospective cohort of HD and PD patients in The Netherlands.
Subjects and methods

Subjects
In The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), a large prospective multicentre cohort study, end-stage renal disease patients are followed from the initiation of dialysis until transplantation or death. All incident dialysis patients in 38 dialysis units in The Netherlands were consecutively invited to participate in the study. Patients had to be 18 years or older with dialysis as their first renal replacement therapy. Details on the design and methods of NECOSAD are described elsewhere [15] .
For the current analyses we included HD and PD patients new on chronic dialysis treatment between 1997 and 2006. Because we were interested in the decline of RRF, patients were excluded when they were already anuric at dialysis initiation. To be included, patients had to have measurements of plasma calcium, phosphorus and iPTH concentrations available at baseline. All patients gave informed consent before inclusion, and the study was approved by all local medical ethics committees. The patients were followed until transplantation, death or 1 January 2007.
Data collection
Data on demography, primary kidney disease and comorbidity were collected 0-4 weeks before the start of dialysis treatment. During follow-up, data on RRF, biochemistry and dialysis characteristics were collected at fixed time points, 3 and 6 months after the start of dialysis, followed by 6-month intervals. The time point 3 months after the start of dialysis was considered as the baseline visit.
Primary kidney disease was classified according to the codes of the European Renal Association-Dialysis and Transplantation Association (ERA-EDTA) [16] . Patients were categorized according to Davies' co-morbidity index as having no, intermediate or severe co-morbidity based on the number of co-morbid conditions [17] . The nutritional status was scored on the 7-point scale of the Subjective Global Assessment (SGA), which is a standardized method based on the clinical judgment of the dialysis nurse [18] . We defined malnourishment as an SGA score of 5 or lower. Dialysis dose, expressed as Kt/V urea per week, was calculated as dialysis urea clearance, divided by urea distribution volume (V) according to Watson et al. [19] . For HD patients, dialysis urea clearance was calculated using a second generation Daugirdas formula [20] , and for PD patients, peritoneal Kt/V urea was calculated from a 24-h dialysate collection.
In the HD patients, blood samples were drawn before and after a monitoring dialysis session and again before the following dialysis session. Urine was collected during the entire interdialytic interval. The plasma concentrations used for the calculation of the GFR were the mean of the concentration after a monitoring dialysis session and the concentration before to the next dialysis session. The majority of HD patients received dialysis three times weekly (range 1-4). In the PD patients, a 24-h urine and dialysate collection was done prior to a monitoring visit at the outpatient clinic and a blood sample was drawn at that visit. RRF was expressed as rGFR, calculated as the mean of creatinine and urea clearance adjusted for body surface area (ml/min/ 1.73 m 2 ). The rGFR was determined at 3 and 6 months after the start of dialysis therapy and every 6 months onwards. The rGFR level was set to zero when urine production was <200 ml/24 h. When a patient had a rGFR value of zero at two successive time points, we defined the patient as anuric from the first time point that rGFR was zero.
Plasma calcium, phosphorus and iPTH were measured by standard laboratory techniques in the different centres. Albumin was measured by bromocresol green (BCG) or purple (BCP) method, depending on the participating centre. Calcium concentrations (mg/dl) were corrected for the albumin concentration (g/dl) using the formula [Corrected calcium = calcium + 0.8 × (4 -albumin)] [21, 22] . To calculate the Ca × P product in mg 2 /dl 2 , we multiplied the corrected calcium concentration by the phosphorus concentration, each in mg/dl.
The plasma concentrations of calcium, phosphorus, Ca × P product and iPTH were classified into categories below, at or above the targets recommended in the K/DOQI guideline [21] . This guideline recommends serum concentrations of corrected calcium between 8.4 and 9.5 mg/dl (2.10 and 2.37 mmol/l) and serum phosphorus concentrations between 3.5 and 5.5 mg/dl (1.13 and 1.78 mmol/l). Ca × P product concentrations should be <55 mg 2 /dl 2 (<4.4 mmol 2 /l 2 ), and iPTH concentrations should range from 150 to 300 pg/ml (15.8 to 31.6 pmol/l). Because the greater part of the study period was before publication of the K/DOQI guideline, nephrologists probably did not aim for these targets. The resulting large variation enabled us to study the effects of K/DOQI targets on RRF.
Statistical analysis
Standard descriptive statistics were used to examine differences between HD and PD patients. All analyses were stratified for treatment modality (HD or PD) as reported 3 months after the start of dialysis. Plasma calcium, phosphorus, Ca × P product and iPTH concentrations were analysed in categories based on the K/DOQI guideline [23] . Patients who had plasma concentrations below or above the targets were compared with patients who met the targets (reference category). ANOVA testing was applied to compare baseline rGFR values less than, at and greater than the advised target ranges.
We evaluated hazard ratios (HRs) for becoming anuric during the first 3 years of dialysis therapy utilizing Cox proportional hazards models, stratified for treatment modality, and controlling for baseline rGFR, calcium, phosphorus, iPTH, age, sex, co-morbid conditions, nutritional status (SGA), systolic and diastolic blood pressure, urinary protein loss and use of anti-hypertensive drugs. A separate multivariable model was used to calculate the HR for Ca × P product. This model contained the same variables except for calcium and phosphorus. Patients were censored at the time of death, renal transplantation or lost to follow-up. Because the cut-off points in the K/DOQI guideline could be considered as arbitrary, we repeated all analyses with calcium, phosphorus, Ca × P product and iPTH as continuous variables.
In addition, generalized linear mixed models for repeated measures were applied to analyse the effects of mineral metabolism, based on the K/DOQI guideline, on the decline of RRF over the first 3 years of dialysis treatment. This method takes into account the correlation between repeated measurements within the same patient. All available time points in the first 3 years after dialysis initiation, i.e. 3, 6, 12, 18, 24, 30 and 36 months after the start of dialysis, were included in the analyses. The multivariate model contained calcium, phosphorus, iPTH, systolic and diastolic blood pressure and proteinuria as repeatedly measured variables. Additional adjustments were applied for age, sex, co-morbidity score, nutritional status and use of antihypertensive medication as recorded at baseline. A separate multivariate model, which contained the same variables except for calcium and phosphorus, was applied to analyse the effect of the Ca × P product on the decline of RRF. In all general linear mixed models, we also adjusted for time and the interaction between time and the variable of interest, i.e. time * calcium, time * phosphorus and time * Ca × P product, respectively.
All statistical analyses were performed using the SAS statistical software, version 9.1 (SAS Institute; Cary, NC, USA). A P-value <0.05 was considered to indicate statistical significance.
Results
Description
From a total of 2004 patients, we had to exclude 298 patients because they had not collected urine at any time point in the study. In addition, we excluded 130 patients who were already anuric at the baseline visit. Finally, 104 patients were excluded due to missing information on mineral metabolism at baseline. The remaining 1468 patients were included in the analyses. Compared to the included patients, To convert serum albumin in g/dl to g/l, multiply by 10; plasma calcium in mg/dl to mmol/l, multiply by 0.2495; plasma phosphorus in mg/dl to mmol/l, multiply by 0.3229; plasma iPTH in pg/ml to ng/l, multiply by 1.
the excluded patients were older and they more often had a high co-morbidity score. Other baseline characteristics were not different between included and excluded patients. The included patients had a mean age of 59 years, 62% were males and 61% were treated with HD. Patient characteristics 3 months after the start of dialysis treatment are summarized in Table 1 .
Decline of RRF
At baseline, the mean (SD) rGFR was 4.0 (2.7) ml/min/ 1.73 m 2 in HD patients and 4.6 (2.9) ml/min/1.73 m 2 in PD patients (P < 0.0001). When we compared baseline rGFR values in categories of plasma concentrations as advised in the K/DOQI guideline for bone metabolism and disease, we found that GFR differed significantly between HD and PD patients with plasma phosphorus below, at or above the target range (P < 0.0001). Patients with plasma concentrations above 5.5 mg/dl had the lowest GFR values. Also HD and PD patients with plasma Ca × P product values >55 mg 2 /dl 2 had lower rGFR values than patients who met the target (P < 0.0001). The results of this analysis are presented in Table 2 .
During the first 3 years of dialysis, 256 of 899 HD patients and 99 of 569 PD patients died. After 2 years of follow-up, 77% of the HD patients and 88% of the PD patients were still alive. There were 136 HD patients (15%) and 67 PD patients (12%) who became anuric in the first 3 years of dialysis treatment. Kaplan-Meier curves for time until loss of RRF in HD and PD patients are shown in Figure 1 . The mean (SD) time until patients became anuric was 32.4 (11.5) months for the HD patients, and 34.1 (9.1) months for the PD patients (P < 0.01).
Cox proportional hazards models were used to calculate crude and adjusted HRs for total loss of RRF in categories of patients that had plasma levels less than, at or greater than the targets advised in the K/DOQI guideline. In the unadjusted analyses, we found that PD patients with a baseline plasma calcium concentration above the target range had an increased risk of becoming anuric [HR: 2.2; 95% confidence interval (CI): 1.1-4.2]. HD patients with hyperphosphataemia had a 60% higher risk of becoming anuric within 3 years after the start of dialysis when compared to HD patients who met the target for phosphorus (HR: 1.6; 95% CI: 1.1-2.3). Moreover, a Ca × P product concentration >55 mg 2 /dl 2 was associated with a significantly elevated HR of 1.7 (95% CI: 1.2-2.4) in the HD patients, but not in the PD patients. We could not detect any statistically significant effects of iPTH on the risk of becoming anuric (data not shown). In the multivariable models, the effects of plasma concentrations were no longer statistically significant. Only HD patients with iPTH levels above target had a lower risk of becoming anuric compared to patients who met the iPTH-target (HR: 0.5; 95% CI: 0.3-1.0). Adjusted HRs are presented in Table 3 . We obtained comparable findings after repeating the multivariable analyses with plasma calcium and phosphorus concentrations as continuous variables, instead of applying the K/DOQI cutoff values, or after removing proteinuria from the model. When we removed baseline rGFR from the multivariate model, the observed effects were similar to those from the crude analyses.
To analyse the decline of RRF over time, we applied general linear mixed models for repeated measures. Results from the multivariate model are depicted in Figures 2 (HD patients) and 3 (PD patients). Both in HD and PD patients, there was no significant difference in the rate of decline between the different phosphorus categories. The rate of decline in rGFR was also not significantly different in HD and PD patients who had too high Ca × P product levels when compared to patients who met the target. When we repeated these analyses with additional interaction terms for time with potential confounders for progression such as proteinuria and blood pressure, this did not alter our conclusions.
To verify whether the results were influenced by baseline rGFR, we repeated all the mixed models-analyses in subgroups of patients with a high or a low baseline rGFR level. Subgroups were defined based on the median rGFR value (HD: 3.48 ml/min/1.73 m 2 ; PD: 4.24 ml/min/1.73 m 2 ). In this additional analysis, we observed similar trends for the rate of decline in the different subgroups (data not shown). To convert serum albumin in g/dl to g/l, multiply by 10; plasma calcium in mg/dl to mmol/l, multiply by 0.2495; plasma phosphorus in mg/dl to mmol/l, multiply by 0.3229; plasma iPTH in pg/ml to ng/l, multiply by 1.
Discussion
This study demonstrates that disordered mineral metabolism is not significantly associated with rate of decline of RRF in the HD and PD patients. Differences in decline in RRF between the categories for plasma calcium, phosphorus, Ca × P product and iPTH concentrations were mainly attributable to the baseline rGFR value. The effects were similar in the PD patients when compared to the HD patients.
Our study is one of the first studies to examine the role of disturbances in mineral metabolism with deterioration of RRF in dialysis patients. We found that 15% of the HD patients and 12% of the PD patients became anuric during the first 3 years of dialysis treatment, whereas Moist et al. reported proportions of 38% and 69%, respectively, during 18 months of dialysis therapy [23] . These discrepant findings are likely to be due to differences in methodology. In our study, we were unable to determine the decline in RRF during the first 3 months of dialysis treatment. Because rGFR measurements were often missing at the start of dialysis, we had to apply the rGFR values measured at 3 months after the start of dialysis as baseline values. As a result, we possibly underestimated the decline of RRF. Also other factors might have contributed to the discrepant findings. First, there were small differences in the methods of determining urine volume. Second, there were important differences in case-mix, such as lower proportions of diabetic and black patients in our study. Finally, the baseline RRF was higher in the study of Moist et al., making a higher rate of decline of RRF possible.
Several cross-sectional studies have shown an association of the plasma phosphorus concentration with the level of RRF in patients with rGFR values <40 ml/min. A metaanalysis of these studies has shown that a higher protein intake, and consequently a higher phosphorus intake, accelerates the decline in renal function in CKD patients [11] . This finding is in accordance with a study of Schwarz et al. in a historical cohort of male US veterans with CKD stage I-V who were not yet on dialysis [13] . In this cohort, the authors found elevated relative risks of progression of CKD (defined as the composite of start of renal replacement therapy or doubling of serum creatinine) in patients with higher serum phosphorus and Ca × P product. In our study, we applied two methods to study both the long-term (Cox regression based on baseline values) and short-term (general linear mixed models for repeated measurements) effects of disordered mineral metabolism. However, neither of those methods showed any significant associations with decline in RRF. After adjustment for the baseline rGFR level, associations were no longer statistically significant, while in pre-dialysis patients the associations were independent of baseline renal function [12] [13] [14] .
We could not detect a significant association between plasma calcium and loss of RRF, while some other studies found contradictory results. Moist et al. observed in HD and PD patients that higher serum calcium levels were independently associated with decreased risk of RRF loss [23] . Because only few patients in our study had calcium levels <8.4 mg/dl (7% of HD and 2% of PD patients), we were unable to draw any firm conclusions about the influence of hypocalcaemia.
The only significant finding in this study was that elevated iPTH levels were associated with a decreased risk of becoming anuric in HD patients. Although there is only little direct experimental or clinical evidence for a role of elevated iPTH on the progression of renal failure [7] , it is difficult to link the presence of (secondary) hyperparathyroidism to a decreased risk of becoming anuric. Possibly, this association could be explained by administered vitamin D analogues, since these agents have been linked to lowering of proteinuria [24] and to attenuation of the progression of kidney failure in both inflammatory and noninflammatory models of CKD [7, 25] . Also an excess of the novel phosphaturic hormone fibroblast growth factor 23 (FGF-23) might be a potential culprit in the progression Adjusted curves for decline in RRF over time in categories of (A) plasma calcium, (B) phosphorus (P = 0.11) and (C) Ca × P product (P = 0.27) in HD patients. (A) Multivariate model: time, calcium, calcium * time, phosphorus, iPTH, age, sex, co-morbidity, nutritional status, systolic and diastolic blood pressure, proteinuria, use of anti-hypertensive medication. The group of HD patients with plasma calcium <8.4 mg/dl was too small to obtain reliable effect estimates after 24 months. P-values for differences between categories (main group effect). (B) Multivariate model: time, phosphorus, phosphorus * time, calcium, iPTH, age, sex, co-morbidity, nutritional status, systolic and diastolic blood pressure, proteinuria, use of anti-hypertensive medication. (C) Multivariate model: time, Ca × P product, Ca × P product * time, iPTH, age, sex, co-morbidity, nutritional status, systolic and diastolic blood pressure, proteinuria, use of anti-hypertensive medication.
of CKD. A recent study of Fliser et al. demonstrated, in a cohort of 227 CKD patients, that FGF-23 is an independent predictor of progression of renal disease in patients with non-diabetic CKD [26] . Unfortunately, FGF-23 was not measured in our study. Fig. 3 . Adjusted curves for decline in RRF over time in categories of (A) plasma calcium, (B) phosphorus (P = 0.96), and (C) Ca × P product (P = 0.70) in PD patients. (A) Multivariate model: time, calcium, calcium * time, phosphorus, iPTH, age, sex, co-morbidity, nutritional status, systolic and diastolic blood pressure, proteinuria, use of anti-hypertensive medication. The group of PD patients with plasma calcium <8.4 mg/dl was too small to obtain a reliable effect estimate after 30 months. (B) Multivariate model: time, phosphorus, phosphorus * time, calcium, iPTH, age, sex, co-morbidity, nutritional status, systolic and diastolic blood pressure, proteinuria, use of anti-hypertensive medication. (C) Multivariate model: time, Ca × P product, Ca × P product * time, iPTH, age, sex, co-morbidity, nutritional status, systolic and diastolic blood pressure, proteinuria, use of anti-hypertensive medication.
The major limitation of our study is that data on medications that could interfere in the relationship between mineral metabolism and the decline of RRF, such as vitamin D and phosphate binders, were incomplete. Our study has some additional limitations. First, rGFR levels were not available for each patient at every time point. Because urine collection was sometimes impossible or unreliable, rGFR calculations might have been inaccurate in the final phase of ESRD. We believe, however, that this shortcoming hardly influenced our results, because we considered a patient as being anuric when urine production was <200 ml/24 h at two successive time points in the study and these lowest values of urine production (and rGFR) were not considered in the analyses. Finally, iPTH measurements were not centrally performed, but by various first-generation immunometric iPTH-assays depending on the different participating centres.
In our study, we could not demonstrate that higher plasma phosphorus leads to a faster decline in RRF in dialysis patients. However, this hypothesis is well founded by evidence from animal studies. Animal models of CKD showed that a high plasma phosphorus concentration leads to the precipitation and deposition of calcium-phosphorus micro crystals in the tubular lumen, peritubular space, capillaries and the interstitium of the kidney, and is thus responsible for an inflammatory reaction. This leads to interstitial fibrosis and tubular atrophy, resulting in progressive loss of RRF [27] . Additional evidence for a pathophysiological role of phosphorus is provided by a rat model of CKD. Rats with CKD that received phosphate-binding drugs, showed less intrarenal calcium-phosphorus deposition and interstitial fibrosis, and less severe renal function loss compared to the rats not receiving such medication [28] .
Mechanisms similar to those observed in animal models could explain the associations of phosphorus concentration with decline in RRF that were observed in studies among pre-dialysis patients [12] [13] [14] . The discrepancies between studies in pre-dialysis patients and our study indicate that the associations between mineral metabolism and RRF are different, depending on the stage of CKD. While disorders of mineral metabolism are important determinants of renal function in the pre-dialysis phase, we can speculate that once dialysis treatment has been started, there are other factors that are dominating. Possible factors might include fluctuations in blood pressure or hypovolaemic episodes [29] . In addition, the prescription of medications could explain this difference since dialysis patients typically receive higher doses of phosphate binders than non-dialysis-dependent CKD patients. Keeping mineral metabolism, especially plasma phosphorus concentrations, in control can delay the deterioration of RRF during the pre-dialysis phase, but not anymore during dialysis treatment. Therefore, it is of major importance to treat disturbances in mineral metabolism thoroughly before the start of renal replacement therapy.
In conclusion, we found that disordered mineral metabolism is not a risk factor for decline of RRF in dialysis patients. Differences between categories of plasma calcium, phosphorus and Ca × P product levels were mainly attributable to the baseline rGFR value.
